Verrica Q1 net loss narrows to $6.6M; raised $32.5M; YCANTH PDUFA July 23, 2023

Verrica Pharmaceuticals Inc.

2023-Q1 EPS reported -$0.15 revenue$37,000

Net loss of $6.6M ($0.15 GAAP EPS) vs $8.5M ($0.31) in Q1 2022; non-GAAP net loss $5.5M ($0.13).
Cash and equivalents $60.0M as of March 31, 2023; management expects runway into Q1 2024.
PDUFA goal date of July 23, 2023 for YCANTH (VP-102) for molluscum contagiosum; no FDA-approved therapy exists.
Raised $32.5M gross proceeds in February 2023 underwritten offering to support pre-commercial activities and VP-315 trial.
VP-315 advanced into Part 2 of Phase 2 study for basal cell carcinoma; Part 3 expected to start first half 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $37,000, net income $6.6 million, EPS $0.15 per share.

Period: the first quarter ended March 31, 2023
Revenue: $37,000
Net income: $6.6 million
EPS: $0.15 per share
Result: reported results

Exact text from the filing

million underwritten offering of common stock and pre-funded warrants. Financial Results First Quarter 2023 Financial Results • Verrica recognized collaboration revenues of $37,000 in the first quarter of 2023 compared to $0.4 million for the same period in 2022 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd (“Torii”).

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-138946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.